Reportstack has announced a new market research publication on Global Dermatological Drugs Market 2014-2018 which forecasts that the market is expected to grow at a CAGR of 4.29 percent over the period 2013-2018. One of the key factors contributing to this market’s growth is an increase in the aging population worldwide. The Global Dermatological Drugs market has also been witnessing a spurt in the use of biologics. However, the risk of adverse side effects associated with dermatological drugs could pose a challenge to the growth of this market.
The Global Dermatological Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, EMEA and APAC regions; it also covers the Global Dermatological Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this space include AbbVie Inc., Galderma S.A., Johnson & Johnson Ltd., Novartis AG, Stiefel Laboratories Inc., and Valeant Pharmaceuticals International Inc.
Other vendors mentioned in the report are Actavis plc, Allergan Inc., Almirall SA, Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol Myers Squibb Co., Celgene Corp., Eisai Co. Ltd., Eli Lilly and Co., Genentech Inc., Incyte Corp., Isotechnika Inc., LEO Pharma A/S, Merck & Co. Inc., Mylan Pharmaceuticals Inc., Pfizer Inc., and UCB SA.
Key questions answered in this report:
What will the market size and growth rate be in 2018?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by key vendors?
What are the strengths and weaknesses of each of these key vendors?
To view the table of contents and know more details please visit Global Dermatological Drugs Market 2014-2018 report.